Latest News

What does personalised medicine mean for you?

Source: bbc.com Medicine has always been personal to some extent – a doctor looks for the best way to help the patient sitting in front of them. But with advances in technology, it is becoming possible to use the most unique of characteristics – our genomes – to tailor treatments for individuals. Genomes are made […]

Read More

The Testimony of an Oncofocus Patient

Note: In order to respect the privacy of the patient, his/her identity will not be revealed. I was diagnosed with terminal bowel cancer in March 2018. I started radiotherapy, which worked well. The tumour then started to cause a build up of fluid in my abdomen, which chemotherapy helped to reduce. However, when the first […]

Read More

Using Tumor Genomic Profiling to Guide Treatment Selection Extends Survival in Advanced Sarcoma

The results of a new study, underscoring the value of precision medicine in advanced sarcoma, showed that patients with heavily pretreated sarcoma who received treatment in accord with their mutational profile attained better outcomes than patients who did not (Abstract 11018). Most notably, median overall survival reached 22.1 months for patients treated with agents targeting […]

Read More

Immunotherapy: new hope in the battle against cancer

Immunotherapy is a burgeoning sector that heralds a breakthrough against the world’s second-most deadly disease. Dr Mike Tubbs explains how investors can benefit too. Cancer is the world’s second-biggest killer. The disease is responsible for around one in six deaths globally; 9.6 million people succumbed to it in 2018, while 18.1 million new cases were […]

Read More

Comprehensive Tumor Profiling Promises New Therapeutic Options for Patients with Advanced Cancer

The WINTHER trial***, NCT01856296, led by investigators from Vall d’Hebron Institute of Oncology – VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave Roussy (France) (Jean-Charles Soria), Centre Léon Bérard (France) (Pierre Saintigny), Segal Cancer Centre, McGill University (Canada) (Wilson H. Miller), UT MD Anderson Cancer Center (USA) (Jordi Rodon and Apostolia-Maria Tsimberidou) and […]

Read More

Genomic Profiling in Sarcoma Shows Potential in Guiding Clinical Management

A new single-center report has found that the results of next-generation sequencing (NGS)–based molecular profiling for non–GI stromal tumor (non-GIST) sarcomas provided information used to effectively guide clinical management. A team of authors led by Spandana Boddu, a research assistant at Moffitt Cancer Center in Tampa, Florida, analyzed data from 114 patients with a diagnosis […]

Read More

Mutations Matter: Cholangiocarcinoma Tumor Profiling Awareness

At least half of patients with cholangiocarcinoma have mutations in their tumors that may be treatable with targeted drugs or immunotherapies that are either experimental or approved for other cancer types. These are available through clinical trials. Yet when surveyed, half of patients with this diagnosis said their tumor tissue hadn’t undergone molecular profiling to […]

Read More

Cancer Conferences Participation. June 2019

Between the 24th and 28th of June, Oncologica will participate in two relevant Cancer Conferences to be held in Cyprus. The 36th International Conference on the Advances in the Applications of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells. Date: June 24-26, 2019. Venue: Grecian Park Hotel, Konnos Bay, Cyprus One of […]

Read More

FDA Approves First Immunotherapy for Breast Cancer

Atezolizumab for Triple-Negative Disease Nick Mulcahy March 08, 2019 The US Food and Drug Administration today granted accelerated approval to atezolizumab (Tecentriq, Genentech/Roche) plus the chemotherapy nab-paclitaxel (Abraxane, Celgene) for the first-line treatment of unresectable locally advanced or metastatic, PD-L1-positive triple-negative breast cancer (TNBC). Atezolizumab is the first immunotherapy to be approved for breast cancer. […]

Read More

Genomics and cancer treatment: new events will showcase developments

The government hopes genome sequencing technology will improve the treatment of cancer A series of NHS and healthcare events are taking place over the coming weeks to spark a conversation among healthcare professionals about genomics. They will help educate healthcare professionals about the benefits of genomics – the practice of using people’s DNA and genetic […]

Read More

Oncofocus Cancer Test is now covered by all leading health insurers

Following signature of an agreement between Oncologica UK Ltd and another UK private medical insurer, all the leading UK health insurers’ customers now have access to the Oncofocus Cancer Test. The Oncofocus Cancer Test is the world’s most comprehensive genomic profiling platform test that enables oncologists to select precisely the most effective targeted therapies and […]

Read More

Prof U. Tirelli: The best cure against cancer is a test

Analysis of genetic mutations in cancer cells can be used to identify precisely the correct targeted therapies for patients. This information is therefore of crucial importance in choosing the correct therapeutic approach for each type of cancer. Oncologists today have limited information with regard to the biological characteristics of a tumour which can be used […]

Read More